Template:Oral hypoglycemics and insulin analogs: Difference between revisions
Content deleted Content added
update, no indication that glucagon receptor agonists like Retatrutide are developed for diabetes. |
|||
| Line 21: | Line 21: | ||
| list3 = |
| list3 = |
||
*[[Insulin detemir]]<sup>#</sup> |
*[[Insulin detemir]]<sup>#</sup> |
||
*[[Insulin icodec]]<sup>†</sup> ([[Insulin icodec/semaglutide|+semaglutide]]) |
|||
*[[Insulin glargine]]<sup>#</sup> ([[Insulin glargine/lixisenatide|+lixisenatide]]) |
*[[Insulin glargine]]<sup>#</sup> ([[Insulin glargine/lixisenatide|+lixisenatide]]) |
||
*[[NPH insulin]] |
*[[NPH insulin]] |
||
| Line 104: | Line 105: | ||
}} |
}} |
||
| group2 = [[Glucagon-like peptide-1 receptor agonist|GLP-1 |
| group2 = [[Glucagon-like peptide-1 receptor agonist|GLP-1 receptor agonists]] |
||
| list2 = |
| list2 = |
||
*[[Albiglutide]]<sup>‡</sup> |
*[[Albiglutide]]<sup>‡</sup> |
||
*[[Danuglipron]] |
*[[Danuglipron]]<sup>†</sup> |
||
*[[Dulaglutide]] |
*[[Dulaglutide]] |
||
*[[Exenatide]] |
*[[Exenatide]] |
||
*[[Liraglutide]] |
*[[Liraglutide]] |
||
*[[Lixisenatide]] |
*[[Lixisenatide]] |
||
*[[Lotiglipron]] |
*[[Lotiglipron]]<sup>†</sup> |
||
*[[Orforglipron]]<sup>§</sup> |
*[[Orforglipron]]<sup>§</sup> |
||
| ⚫ | |||
*[[Semaglutide]] |
*[[Semaglutide]] |
||
*[[Taspoglutide]]<sup>†</sup> |
*[[Taspoglutide]]<sup>†</sup> |
||
{{navbox|child| |
|||
group1=[[GLP1 poly-agonist peptides|GLP-1/GIP dual agonists]] |
|||
|list1= |
|||
*[[Tirzepatide]] |
*[[Tirzepatide]] |
||
}} |
|||
| group3 = [[Dipeptidyl peptidase-4 inhibitor|DPP-4 inhibitor]]s/"gliptins" |
| group3 = [[Dipeptidyl peptidase-4 inhibitor|DPP-4 inhibitor]]s/"gliptins" |
||
| Line 135: | Line 139: | ||
*[[Trelagliptin]] |
*[[Trelagliptin]] |
||
*[[Vildagliptin]] |
*[[Vildagliptin]] |
||
| group4 = [[Free fatty acid receptor 1| FFAR1 agonists]] |
|||
| list4 = |
|||
*[[Fasiglifam]]<sup>†</sup> |
|||
}} |
}} |
||
|group3 = Other |
|group3 = Other |
||
| Line 156: | Line 156: | ||
*[[Voglibose]] |
*[[Voglibose]] |
||
| group3 = [[Amylin]] |
| group3 = [[Amylin]] analogs and [[DACRA]]s |
||
| list3 = |
| list3 = |
||
| ⚫ | |||
*[[Pramlintide]] |
*[[Pramlintide]] |
||
| Line 183: | Line 184: | ||
* [[Alogliptin/metformin]] |
* [[Alogliptin/metformin]] |
||
* [[Canagliflozin/metformin]] |
* [[Canagliflozin/metformin]] |
||
*[[Cagrilintide/semaglutide]]<sup>§</sup> |
|||
* [[Dapagliflozin/metformin]] |
* [[Dapagliflozin/metformin]] |
||
* [[Dapagliflozin/saxagliptin]] |
* [[Dapagliflozin/saxagliptin]] |
||
Revision as of 07:05, 30 November 2023
This template's initial visibility currently defaults to autocollapse, meaning that if there is another collapsible item on the page (a navbox, sidebar, or table with the collapsible attribute), it is hidden apart from its title bar; if not, it is fully visible.
To change this template's initial visibility, the |state= parameter may be used:
{{Oral hypoglycemics and insulin analogs|state=collapsed}}will show the template collapsed, i.e. hidden apart from its title bar.{{Oral hypoglycemics and insulin analogs|state=expanded}}will show the template expanded, i.e. fully visible.